Vyvanse (Lisdexamfetamine) Uses
Vyvanse is FDA-approved for two specific indications: ADHD in patients 6 years and older, and moderate to severe binge eating disorder (BED) in adults. 1
FDA-Approved Indications
1. Attention-Deficit/Hyperactivity Disorder (ADHD)
- Approved for adults and pediatric patients 6 years and older 1
- Starting dose: 30 mg once daily in the morning
- Titration: Increase by 10-20 mg increments at weekly intervals
- Target dose range: 30-70 mg daily
- Maximum dose: 70 mg daily 1
Important limitation: Vyvanse is not approved for children under 6 years of age. While a 2022 study examined its use in preschool children aged 4-5 years, the effect size was smaller than in older children, and this remains an off-label use 2. The 2011 AAP guidelines note that pediatric patients younger than 6 years experienced more long-term weight loss than older patients 3.
2. Moderate to Severe Binge Eating Disorder (BED)
- Approved for adults only 1
- Starting dose: 30 mg once daily
- Titration: Increase by 20 mg increments at weekly intervals
- Target dose: 50-70 mg daily
- Maximum dose: 70 mg daily
- Discontinue if binge eating does not improve 1
Vyvanse is the first and only FDA-approved medication for BED treatment 4, 5. Clinical trials demonstrated significant reductions in binge eating days per week at 50-70 mg daily doses, with benefits maintained up to 52 weeks 5.
Key Clinical Advantages
Vyvanse has lower abuse potential compared to immediate-release amphetamines because it is a prodrug that requires enzymatic conversion by red blood cells to become active 3. The AAP guidelines specifically recommend lisdexamfetamine for adolescents at risk for medication diversion, as it cannot be activated through intranasal or intravenous routes 3. This makes extraction and abuse more difficult compared to other stimulants.
Critical Dosing Adjustments
Renal Impairment
- Severe renal impairment (GFR 15-30 mL/min/1.73 m²): Maximum 50 mg daily
- End-stage renal disease (GFR <15 mL/min/1.73 m²): Maximum 30 mg daily 1
Drug Interactions
Agents altering urinary pH significantly affect amphetamine blood levels:
- Acidifying agents (e.g., ascorbic acid): Decrease blood levels—may need dose increase
- Alkalinizing agents (e.g., sodium bicarbonate): Increase blood levels—may need dose reduction 1
Administration Guidelines
- Take in the morning with or without food
- Avoid afternoon doses due to insomnia risk
- Capsules can be swallowed whole OR opened and mixed with yogurt, water, or orange juice (consume immediately)
- Chewable tablets must be chewed thoroughly
- Never divide a single dose—minimum is one full capsule or tablet 1
Critical Contraindications and Warnings
Absolute contraindications 1:
- Known hypersensitivity to amphetamine products
- Current or recent (within 14 days) MAO inhibitor use
Avoid use in patients with 1:
- Known structural cardiac abnormalities
- Cardiomyopathy
- Serious cardiac arrhythmias
- Coronary artery disease
Mandatory pretreatment screening 1:
- Cardiac assessment (history, family history of sudden death/arrhythmia, physical exam)
- Screen for tics or Tourette's syndrome
- Assess for substance abuse risk (especially in adolescents) 3
Common Pitfalls to Avoid
Do not use for weight loss: Vyvanse is not indicated for obesity treatment. Other sympathomimetic drugs used for weight loss have been associated with serious cardiovascular events 1
Monitor growth in pediatric patients: Closely track height and weight—consider treatment interruption if growth is not as expected 1
Screen for psychiatric risk factors: Before initiating, screen for risk of manic episodes. New psychotic or manic symptoms warrant discontinuation 1
Watch for peripheral vasculopathy: Monitor for digital changes (Raynaud's phenomenon) during treatment 1
The most common adverse effects include dry mouth, decreased appetite, insomnia, headache, and increased heart rate 4, 5. Most are mild to moderate in intensity and rarely lead to discontinuation.